Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.
------------------------------------------------------------
April 23, 2003
INTERNATIONAL IMMUNIZATION NEWS
"Practicalities of the DNA Revolution"
Financial Times (www.ft.com) (04/23/03) P. 23; Brun-Rovet, Marianne
The discovery of the DNA double helix structure 50 years ago was a breakthrough in medical science, and continues to have ramifications today, though the use of DNA knowledge has thus far been limited primarily to diagnostic products like medical tests. Few drugs and other therapeutic treatments have yet to be developed from the information, though some vaccines have come into the market. The slow pace at which DNA data is being translated into treatments for disease is understandable, according to some biotechnology executives, who say that there will undoubtedly be advances based on DNA research in the future; but skeptics are beginning to suggest that DNA structure will never have much of an impact on drug design and delivery. Many of the most celebrated companies working in the DNA field, such as Cambridge Antibody Technologies, have plenty of products in their development programs, but have yet to get any drugs to the market despite touting genome decoding as the way to find drug targets. Vaccine makers Acambis and PowderJect are benefiting from the genomic information through partnerships with major drug firms to bring the vaccines to market.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.